Implementation of regulatory guidance for JAK inhibitors use in patients with immune-mediated inflammatory diseases: An international appropriateness study
V Solitano, P Facheris, M Petersen, F d'Amico… - Autoimmunity …, 2023 - Elsevier
Abstract Background and Aims The Pharmacovigilance Risk Assessment Committee
(PRAC) proposed measures to address severe side effects linked to Janus kinase inhibitors …
(PRAC) proposed measures to address severe side effects linked to Janus kinase inhibitors …
Tofacitinib in ulcerative colitis–Small molecule but large effect
S Harindranath, A Singh - Digestive and Liver Disease, 2024 - Elsevier
We read with great interest the article by Macaluso et al., which explores the efficacy and
safety of tofacitinib in a real-world cohort of patients with ulcerative colitis. The authors …
safety of tofacitinib in a real-world cohort of patients with ulcerative colitis. The authors …
[HTML][HTML] Remission of refractory esophageal lichen planus induced by tofacitinib
V Bieneck, A Decker, A Schmitt-Graeff… - Zeitschrift für …, 2024 - thieme-connect.com
As of now, there exists no established therapy for ELP. Retinoids, which are standard in
treating cutaneous LP, do not exhibit positive effects in ELP. While topical …
treating cutaneous LP, do not exhibit positive effects in ELP. While topical …